Provided by Tiger Trade Technology Pte. Ltd.

Soleno Therapeutics

34.00
+0.24500.73%
Volume:111.21K
Turnover:3.77M
Market Cap:1.76B
PE:87.18
High:34.34
Open:33.87
Low:33.41
Close:33.76
52wk High:90.32
52wk Low:32.63
Shares:51.62M
Float Shares:44.87M
Volume Ratio:0.72
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):0.3900
ROE:6.01%
ROA:2.09%
PB:3.90
PE(LYR):87.18

Loading ...

Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research

TIPRANKS
·
Jan 13

BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners

Reuters
·
Jan 12

Soleno Therapeutics Reverse Premarket Gains, Last Down 1.7%

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Preliminary Q4 Net Revenue Beats Analyst Estimates

MT Newswires Live
·
Jan 12

Soleno Therapeutics Projects 2025 Net Revenue of Up to $191 Million

Reuters
·
Jan 12

Soleno Therapeutics Inc Q4 REV View $81.7 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Inc - 2025 Net Revenue From US Sales of Vykat Xr Since Q2 Expected Between $189 Mln-$191 Mln

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Inc - Achieves Profitability and Positive Cash Flow

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Inc - Vykat Xr Discontinuation Rate Due to Adverse Events About 12%, as of Q4 End

THOMSON REUTERS
·
Jan 12

Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?

Simply Wall St.
·
Jan 09

Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome

Reuters
·
Jan 05

BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise

Reuters
·
Dec 23, 2025

Soleno Therapeutics (SLNO) Valuation Check After Wolfe’s Bullish Call Challenges Short-Seller Concerns

Simply Wall St.
·
Dec 04, 2025

Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris

Dow Jones
·
Dec 04, 2025

How Does Wolfe Research’s Support Shape Soleno Therapeutics’ (SLNO) Credibility Amid Heightened Scrutiny?

Simply Wall St.
·
Dec 02, 2025

Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Kevin Norrett

Reuters
·
Nov 20, 2025

Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement

Reuters
·
Nov 20, 2025

Soleno Therapeutics Initiated at Outperform by Wolfe Research

Dow Jones
·
Nov 19, 2025

Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia

Reuters
·
Nov 19, 2025